822 related articles for article (PubMed ID: 29986042)
21. Estimating the effect of lipid-lowering agents on novel subtypes of adult-onset diabetes.
Ye J; Guo K; Li J; Li X; Zhou Z; Yang L
Diabetes Metab Res Rev; 2024 May; 40(4):e3793. PubMed ID: 38661109
[TBL] [Abstract][Full Text] [Related]
22. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
[TBL] [Abstract][Full Text] [Related]
23. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
24. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
25. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
26. Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.
Huang Q; Zhang Q; Cao B
Brain Behav; 2024 Jun; 14(6):e3543. PubMed ID: 38837845
[TBL] [Abstract][Full Text] [Related]
27. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
28. Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials.
Filippatos TD; Panagiotopoulou T; Tzavella E; Elisaf MS
J Cardiovasc Pharmacol Ther; 2018 May; 23(3):187-191. PubMed ID: 29409336
[TBL] [Abstract][Full Text] [Related]
29. Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study.
Li S; Schooling CM
Sci Rep; 2022 Mar; 12(1):3478. PubMed ID: 35241713
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
[TBL] [Abstract][Full Text] [Related]
31. Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study.
Yang G; Schooling CM
J Clin Endocrinol Metab; 2023 Jan; 108(2):385-396. PubMed ID: 36184662
[TBL] [Abstract][Full Text] [Related]
32. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
33. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
34. Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization.
Wu T; Ye L; Wang S; Huang J; Zhang J
Front Pharmacol; 2023; 14():1258018. PubMed ID: 37964871
[No Abstract] [Full Text] [Related]
35. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
36. Combined lipid-lowering therapy.
Karásek D
Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
[TBL] [Abstract][Full Text] [Related]
37. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
[TBL] [Abstract][Full Text] [Related]
38. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
39. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
40. Genetic Association of Lipid-Lowering Drugs with Aortic Aneurysms: A Mendelian Randomization Study.
Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
Eur J Prev Cardiol; 2024 Feb; ():. PubMed ID: 38302118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
